Sandoz, Slayback Pharma partner to launch generic Firazyr

Sandoz is introducing icatibant injection pre-filled syringe to treat acute attacks of rare disease hereditary angioedema in adults 18 years and older.

Sandoz has signed a U.S. commercialization deal with Slayback Pharma for this medicine, which is a generic of Takeda's Firazyr (icatibant injection).

"We are eager to see the positive effects of making generic Icatibant available immediately to people living with this painful and disabling rare disease," said Keren Haruvi, Sandoz president. "This collaboration aligns with our goal to build our injectables portfolio and provide U.S. patients access to affordable generic medicines that work the same as brand-name products."

Hereditary angioedema is a rare disease characterized by recurrent episodes of severe swelling of the skin and mucous membranes. Swelling of the airways and throat can be extremely dangerous and potentially lead to death. Patients also can suffer nausea, vomiting, diarrhea and abdominal pain.

"With our strong developmental capabilities and Sandoz's industry-leading commercialization of its extensive portfolio of generic medicines, we couldn't be more excited to collaborate with Sandoz and help people living with hereditary angioedema," said Ted Smolenski, Slayback vice president of business development.